The development of personalised therapies for cancer patients, such as HER2-targeted therapies for patients with HER2pos breast cancer, requires early and reliable identification of patients for such personalised treatment as well as for monitoring during follow-up periods to confirm response to therapy or detect tumour relapse. This evidence concerns the gene ERBB2 and breast carcinoma.